<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131084">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837277</url>
  </required_header>
  <id_info>
    <org_study_id>SevereHIV</org_study_id>
    <nct_id>NCT01837277</nct_id>
  </id_info>
  <brief_title>Impact of a Raltegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação Bahiana de Infectologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação Bahiana de Infectologia</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current  available antiretroviral (ARV) agents  make possible a successful  treatment of
       virtually all HIV-infected patients, but some problems related to early mortality are still
      of concern, mainly in resources-limited settings. There are several published reports
      showing that such patients are at a significantly higher risk of death during the first
      months of treatment, in comparison with the observed outcomes in developed countries. One of
      the consistently detected risks for early mortality across these reports is the baseline low
      CD4 count, although it does not seem to be the only reason for such outcome. In Brazil and
      other developing countries, there is still a large proportion of AIDS patients who are
      diagnosed with AIDS, or only seek health care for HIV infection late in the course of
      disease. Raltegravir (RAL), the first HIV-1 integrase inhibitor, is a potent and safe ARV
      drug. The available evidence suggest it promotes a faster decline in HIV-1 plasma viremia,
      and a higher increase in CD4 cells count, in comparison with those in Efavirenz (EFV) arm.
      The investigators propose to compare the impact of RAL versus EFV in the early mortality
      rates for severely ill (CD4+ cells count &lt;50 cells/mm3) patients starting ARV therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Parallel Assignment</study_design>
  <primary_outcome>
    <measure>early mortality</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Severely Immunocompromised HIV Patients</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Use of Raltegravir-based regimens</intervention_name>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz-based regimens</intervention_name>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA
             &gt;1,000 copies/ml)

          -  No previous use of any ARV drug (drug-naïve patients)

          -  Presence of clinical symptoms according to Rio de Janeiro / Caracas´ AIDS definition
             (Asthenia, Cachexia/Wasting, Cough, Dermatitis, persistent, Diarrhea, Fever,
             Lymphadenopathy, Candidiasis, oral, or hairy leukoplasia, Central nervous system
             dysfunction, Herpes zoster in individual younger than 60 years of age)), and/or any
             active AIDS-defining condition

          -  Baseline CD4+ cells count equal or lower than 50 cells/mm3

          -  Age equal or higher than 18 years

          -  HIV-1 plasma viral load ≥ 1,000 copies of HIV-1 RNA/ml

        Exclusion Criteria:

          -  Undetectable plasma viral load at screening

          -  CD4 cells count&gt;50 cells/mm3

          -  Asymptomatic individuals
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Estela Luz, RN, MSci</last_name>
    <phone>557132838123</phone>
    <email>eluz5@yahoo.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundação Bahiana de Infectologia/SEI</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40010-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Estela Luz, RN, MSci</last_name>
      <phone>32838123</phone>
      <email>eluz5@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Carlos Brites, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabianna Bahia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Ponze, RN</last_name>
      <phone>5521222739073</phone>
    </contact>
    <investigator>
      <last_name>Mauro Schechter, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priscila Pelaez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Sprinz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundação Bahiana de Infectologia</investigator_affiliation>
    <investigator_full_name>Carlos Brites</investigator_full_name>
    <investigator_title>Senior Investigator</investigator_title>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
